Patterns of use, effectiveness and safety of gadolinium contrast agents: a European prospective cross-sectional multicentre observational study
暂无分享,去创建一个
Valeria Panebianco | Wolfgang Reith | Carlo Cosimo Quattrocchi | Jarl Åsbjørn Jakobsen | Frank H. H. Müller | Olivier Outteryck | Andrés Alcázar | Patricia Fraga | Alexis Sampedro | Radoslaw Pietura | W. Reith | C. Quattrocchi | V. Panebianco | J. Jakobsen | R. Pietura | O. Outteryck | Patricia Fraga | F. Müller | A. Alcázar | Alexis Sampedro
[1] A. Dohan,et al. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study , 2016, Journal of magnetic resonance imaging : JMRI.
[2] G.,et al. Side-Effects of Anti-Inflammatory Drugs , 1987, Inflammation and Drug Therapy Series.
[3] M. Lockhart,et al. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. , 2011, Radiology.
[4] B. Hamm,et al. Tolerability and diagnostic value of gadoteric acid in the general population and in patients with risk factors: results in more than 84,000 patients. , 2012, European journal of radiology.
[5] W. Kucharczyk,et al. Allergic-like Reactions to the MR Imaging Contrast Agent Gadobutrol: A Prospective Study of 32 991 Consecutive Injections. , 2016, Radiology.
[6] Charles Westin,et al. Evaluating the Referring Physician’s Clinical History and Indication as a Means for Communicating Chronic Conditions That Are Pertinent at the Point of Radiologic Interpretation , 2015, Journal of Digital Imaging.
[7] J. Mintorovitch,et al. Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.
[8] S. Schoenberg,et al. Enhancement Characteristics and Impact on Image Quality of Two Gadolinium Chelates at Equimolar Doses for Time-Resolved 3-Tesla MR-Angiography of the Calf Station , 2014, PloS one.
[9] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..
[10] Gerhard Adam,et al. Clinical Safety and Diagnostic Value of the Gadolinium Chelate Gadoterate Meglumine (Gd-DOTA) , 2007, Investigative radiology.
[11] R. Lenkinski,et al. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. , 2018, Radiology.
[12] M Oudkerk,et al. Safety and Efficacy of Dotarem (Gd-DOTA) versus Magnevist (Gd-DTPA) in Magnetic Resonance Imaging of the Central Nervous System , 1995, Investigative radiology.
[13] R. Vliegenthart,et al. Acute adverse events in cardiac MR imaging with gadolinium-based contrast agents: results from the European Society of Cardiovascular Radiology (ESCR) MRCT Registry in 72,839 patients , 2019, European Radiology.
[14] F. Miller,et al. Reactions to Both Nonionic Iodinated and Gadolinium-Based Contrast Media: Incidence and Clinical Characteristics. , 2018, AJR. American journal of roentgenology.
[15] E Herskovits,et al. Comparison of Gadoterate Meglumine and Gadobutrol in the MRI Diagnosis of Primary Brain Tumors: A Double-Blind Randomized Controlled Intraindividual Crossover Study (the REMIND Study) , 2017, American Journal of Neuroradiology.
[16] B. Hamm,et al. Diagnostic efficacy and safety of gadoteric acid MR mammography in 1537 patients. , 2016, European journal of radiology.